Lupin receives EIR from US FDA for its API Manufacturing Facility in Vizag

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its API manufacturing facility located in Visakhapatnam (Vizag), India. The EIR was issued post the last inspection of the facility conducted from March 6 to March 10, 2023. The inspection closed with the facility receiving an inspection classification of "No Action Indicated" (NAI).

"We are happy to have received the EIR for our Vizag facility from the US FDA," said Nilesh Gupta, Managing Director, Lupin. "We remain committed to ensuring the high quality of our products and ensuring the safety of our manufacturing processes."

Shares of Lupin Limited was last trading in BSE at Rs. 834.55 as compared to the previous close of Rs. 818.80. The total number of shares traded during the day was 66232 in over 3577 trades.

The stock hit an intraday high of Rs. 835.65 and intraday low of 813.30. The net turnover during the day was Rs. 55075643.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 EIR USFDA APIManufacturingFacility Visakhapatnam Vizag